SCLERO.ORG
Search

Uptravi® (Selexipag) for Pulmonary Hypertension

Author: Jo Frowde. Scleroderma is highly variable. See Types of Scleroderma. Read Disclaimer
Uptravi is marketed by San Francisco-based Actelion Pharmaceuticals US, Inc.

Uptravi by Actelion is an oral medication for PAHUptravi® (selexipag) is an oral IP prostacyclin receptor agonist marketed by Actelion Pharmaceuticals US, Inc., which was approved by the US FDA for the treatment of pulmonary arterial hypertension in December 2015. Common side effects include headache, diarrhea, jaw pain, nausea, muscle pain (myalgia), vomiting, pain in an extremity, and flushing. ISN.

Uptravi (selexipag). About this treatment for pulmonary hypertension, including the GRIPHON clinical trial results, safety and tolerability, and dosing information. Actelion.

Go to Endothelin Receptors
 
 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.